Opthea Developing Therapy for Eye Diseases

Opthea is developing novel therapies for the treatment of eye diseases.

Opthea's lead compound, OPT-302, blocks two members of the vascular endothelial growth factor family, namely VEGF-C and   VEGF-D, which cause blood vessels to grow and leak. Aberrant blood vessel growth and vascular leakage are hallmarks of several eye diseases including wet age-related macular degeneration (wet AMD).

Opthea is currently investigating OPT-302 in an ongoing Phase 1/2A clinical trial in wet AMD patients. 

Latest News

05 MAY 2016. “Opthea Doses First Patient in Ph2A for OPT-302 in Wet AMD"

read more >>

21 APR 2016. “Opthea Phase 1 wet AMD Clinical Trial with OPT-302 Meets Primary Safety Objective"

read more >>

30 MAR 2016. “Opthea Completes Patient Enrolment for OPT-302 Phase 1 Dose Escalation Trial in Patients with Wet AMD”

read more >>

07 MAR 2016. “Results of EGM”

read more >>
Share Price